Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin.

Health Qual Life Outcomes · 2006 · PMC1479317 · PMID 16696859

Europe PMC DOI

hedged sentence

0.0060

closest p · 0.1× alpha

0.0060

boldest claim

The sentences

borderline significantp = .006actually significant

The decrease in HRQOL was significant in the domain of bodily pain (mean difference = -3.7, p = < .001) and borderline significant in the domain of vitality (mean difference = -3.46, p = .006).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.